NCT06608537View on ClinicalTrials.gov

A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Rectal Cancer
Interventions
DRUG

neoadjuvant SCRT followed by Sintilimab plus CAPOX

Patientsreceived neoadjuvant treatment consisting of SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles) combined with CAPOX (oxaliplatin 130 mg/m2 intravenous infusion over 2 h on day 1, capecitabine 1000 mg/m2 orally twice daily from day 1-14, in every 3-week cycle for two cycles) 1 week later.

Trial Locations (1)

510000

RECRUITING

Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER